Dublin, Aug. 22, 2017 -- The "Worldwide Pediatric Vaccines Market: Doses, Immunization, Cases, Forecast, and Analysis" report has been added to Research and Markets' offering.
Global Pediatric Vaccines Market is expected to cross US$ 40 Billion by the year 2022
Our analysis found that the combination and pneumococcal vaccines was the two leading vaccines segment in 2017 and they continue to dominate the market in future years as well. The market of Combos (Combination vaccines) is thriving as most of the parents believed that if all these vaccines were given separately, than each child would have to take a large number of injections.
"By the Year 2022, 500 Million Pediatrics will be get Immunization"
Our research found that around 500 million infants get immunization by the year 2022 owing to rising concern against vaccine-preventable diseases and growing awareness. This report covers the past and present scenario and the growth prospects of the infants' vaccine (Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap, Polio, Haemophilus influenzae type B, Rotavirus, Varicella, Combination) Vaccines market across the world for the period of 2011-2022.
"Globally 600 Million Doses of Vaccines will be Administrated in Pediatrics"
Our study indicates that that around the globe nearly 600 million doses of vaccines will be administrated in infants by the year 2022 which will be nearly five times the number of influenza doses administered. The number of DTap doses administered in infants is forecast to increase over the years and will cross 50 Million by the year 2022. Report covers detailed information on all the 11 vaccines (Pneumococcal, Rotavirus, Meningococcal, DTap, MMR, Polio, Hepatitis, Varicella, Haemophilus influenzae type B, Influenza, Combination) Vaccines Doses of Vaccines Administered and Forecast.
'Worldwide Pediatric Vaccines Market: Doses, Immunization, Cases, Forecast, and Analysis' is the 2nd edition report on Pediatric Vaccines. This 199 page market research report with 93 Figures and 30 Tables provides data and analysis on Global Pediatric Vaccines Market, Infants Immunized, Number of Vaccine Doses Administered in Pediatric (Infant) (Disease wise) & Key Players.
Vaccine Has Been Extensively Studied From 3 Major Points:
1. Global Pediatric (Infant) Vaccines (Disease wise) Market & Forecast (2011 - 2022)
2. Pediatric (Infants) Immunized (Disease wise) & Forecast (2011 - 2022)
3. Doses of Vaccines Administered in Pediatric (Infant) (Disease wise) & Forecast (2011 - 2022)
11 Vaccines Studied in the Report are as Follows:
1. Influenza
2. MMR (Measles, Mumps, and Rubella)
3. Pneumococcal
4. Meningococcal
5. Hepatitis
6. DTap (Diphtheria, Tetanus, Pertussis)
7. Haemophilus influenzae type B
8. Polio
9. Rotavirus
10. Varicella
11. Combination Vaccine
Companies Vaccines Sales and Forecast:
1. GlaxoSmithKline, plc Sales & Forecast (2011 - 2022)
2. Merck & Co. Sales & Forecast (2011 - 2022)
3. Sanofi Pasteur's Sales & Forecast (2011 - 2022)
4. Pfizer, Inc.'s Sales & Forecast (2011 - 2022)
5. Others Vaccines
Key Topics Covered:
1. Research Findings
2. Global - Pediatric (Infant) Vaccines Market and Forecast
3. Global - Pediatric (Infant) Vaccines Market Share and Forecast
4. Global - Pediatric (Infant) Immunized and Forecast
5. Global - Pediatric (Infant) Immunized Share and Forecast
6. Global - Doses of Pediatric (Infant) Vaccines Administered and Forecast
7. Global - Doses of Vaccines Administered to Pediatric (Infant) Share and Forecast
8. Global - Vaccine Companies Market Share and Forecast
9. Disease wise - Vaccines Market and Forecast
10. Disease wise - Infants Immunized Numbers and Forecast
11. Disease wise - Doses of Vaccines Administered and Forecast
12. Disease wise - Immunization Profile
13. Vaccines Key Players Sales and Forecast
14. Vaccines - Products and Pipeline
15. Top Mergers and Acquisitions in the Vaccine Industry
16. Vaccines and Regulator's Interventions
17. Vaccine Market Drivers
18. Vaccines Market Challenges
For more information about this report visit https://www.researchandmarkets.com/research/3g5954/worldwide
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Vaccines, Pediatrics


Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 



